Ipca Laboratories Limited (NSE: IPCALAB)

Market Cap	361.00B
Revenue (ttm)	82.13B
Net Income (ttm)	5.77B
Shares Out	253.70M
EPS (ttm)	22.73
PE Ratio	62.59
Forward PE	37.32
Dividend	4.00 (0.28%)
Ex-Dividend Date	Aug 6, 2024

Volume	480,652
Open	1,453.80
Previous Close	1,444.15
Day's Range	1,416.10 - 1,455.00
52-Week Range	878.00 - 1,460.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Ipca Laboratories

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1949
• Employees: 17,335
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: IPCALAB

Financial Performance

In 2023, IPCALAB's revenue was 77.06 billion, an increase of 23.33% compared to the previous year's 62.48 billion. Earnings were 5.47 billion, an increase of 16.13%.